The research will be advanced through the integration of cryo-electron microscopy (EM), nuclear magnetic resonance (NMR) spectroscopy, and X-ray diffraction (XRD) which are believed to progress key medical
Under the terms of the collaboration, both the companies will develop novel drug candidates against multiple targets across different therapeutic areas. Initially, NovAliX will employ its protein biochemistry
rIX-FP is indicated for the prophylaxis and treatment of bleeding episodes in patients with congenital Factor IX (FIX) deficiency. CSL Behring Global Clinical R&D senior vice president Russell
Gleevec is the registered trade name for Imatinib, a specific inhibitor of tyrosine kinase BCR-ABL. BCR-ABL is a fusion protein created by the Philadelphia Chromosome abnormality that characterizes
NIOX MINO enables management of airway inflammation and thus is believed to play a critical role in effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases
The upgradation includes adoption of Oracle Argus Safety 7.0, a safety database and regulatory reporting system. Oracle Argus Safety is believed to help Novella provide efficiencies and the
According to the company, the supplements which largely cater to health-conscious families, travelers and fitness enthusiasts have been developed a result of rise in demand for wellness supplements.
The process involves non-enzymatic method for deriving stromal vascular fraction from 60cc’s of adipose tissue, which is believed to increase the yield in manufacturing stromal vascular fraction compared
This is the fourth milestone achieved in 2011 and represents a total of EUR 10.5m of milestones achieved within the year, the company said. The milestone was achieved
The patent entitled ‘Method of Attaching an Antimicrobial Cationic Electrolyte to the Surface of a Substrate,’ has been granted by the US Patent and Trademark Office (USPTO). The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.